top of page

KLUS Pharma to attend BIO-Europe Spring 2024

KLUS Pharma will attend Bio-Europe Spring partnering event held live in Barcelona, Spain from March 18-20 and virtually from March 26-27, 2024. KLUS Pharma is the US subsidiary of Kelun-Biotech, a mid-sized innovative biopharma company based in Chengdu, China. Kelun-Biotech is advancing a broad pipeline of small molecules, monoclonal antibodies, and antibody drug conjugates (ADCs) for the treatment of cancer, autoimmune, metabolic, and cardiovascular diseases. With over ten clinical-stage assets and dozens of promising preclinical candidates, we are actively seeking strategic partners to help accelerate the global development of these promising therapeutic candidates. In addition, we are also seeking in-licensing opportunities for the Greater China market, including innovative therapeutics in oncology, autoimmune, metabolic, and cardiovascular diseases areas. Clinical-stage assets with preliminary safety and efficacy data are preferred. We also consider selective generic products suitable for the China market in the following therapeutic spaces: neurology, infectious disease, reproductive health, and fertility treatments.

Refer to the link below to request a meeting with KLUS Pharma through the BIO partnering system!
We look forward to meeting potential collaborators at the event!

Business Development Team

Monday, March 4, 2024

bottom of page